<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03971500</url>
  </required_header>
  <id_info>
    <org_study_id>NFH20190529</org_study_id>
    <nct_id>NCT03971500</nct_id>
  </id_info>
  <brief_title>1-month vs 12-month DAPT for ACS Patients Who Underwent PCI Stratified by IVUS: IVUS-ACS and ULTIMATE-DAPT Trials</brief_title>
  <official_title>Comparison of 1-month Versus 12-month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents Guided by Either Intravascular Ultrasound or Angiography in Patients With Acute Coronary Syndrome: The Prospective, Multicenter, Randomized, Placebo-controlled IVUS-ACS and ULTIMATE-DAPT Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing First Hospital, Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing First Hospital, Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multicenter, randomized, double-blind, placebo-controlled trials.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 3486 subjects with ACS who met inclusion criteria and do not have any exclusion&#xD;
      criterion will be randomized to IVUS- or Angiography-guidance group (first randomization). In&#xD;
      the IVUS-guidance group, IVUS will be used to evaluate the lesion's specificity and to&#xD;
      measure lesion length, landing zone, and reference vessel diameter prior-to stenting; and to&#xD;
      assess stent expansion, extension, apposition, and possible complications after stent&#xD;
      implantation. The IVUS- defined criteria for the optimal stent deployment included: 1) the&#xD;
      minimal stent area (MSA) in the stented segment is &gt;5.0 mm^2, or 90% of the MLA at the distal&#xD;
      reference segments; 2) plaque burden 5-mm proximal or distal to the stent edge is &lt;55%; and&#xD;
      3) absence of &gt;Type B edge dissection. Further treatment will be required if stenting&#xD;
      procedure is defined as suboptimal according to IVUS definition. IVUS will be not allowed to&#xD;
      be used in the Angiography-guidance group.&#xD;
&#xD;
      Those patients who have had no MACCE or major bleeding (BARC 3 or 5) within 30 days and have&#xD;
      continued on aspirin and ticagrelor for 30 days without interruption for &gt;48 hours will be&#xD;
      randomized 1:1 to:&#xD;
&#xD;
        1. Ticagrelor plus+ matching placebo for an additional 11 months (SAPT group)&#xD;
&#xD;
        2. Ticagrelor plus aspirin (study drug) for an additional 11 months (DAPT group) Follow-up&#xD;
           of all subjects will continue for 1 year with an option for additional follow-up to 3&#xD;
           years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will undergo 1:1 randomization (first randomization) to either IVUS-guided DES implantation which will be the treatment group or Angio-guided DES implantation which will be the control group based on an online Clinical Research Data Management Platform. The initiation of the trial is defined as the time of randomization. After study subjects' enrollment and randomization, the study intervention will take place immediately. The follow-up visits for the primary TVF endpoint are scheduled at 1, 4, 6, and 12 months after the index procedure.&#xD;
Patients will undergo 1:1 randomization (second randomization) to either SAPT which will be the treatment group or DAPT which will be the control group based on an online Clinical Research Data Management Platform. The follow-up visits for the primary superiority bleeding endpoint and non-inferiority ischemic endpoint are scheduled at 3, 5, and 11 months after the second randomization.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target vessel failure (TVF)</measure>
    <time_frame>12 months</time_frame>
    <description>The difference in TVF will be calculated from 0 month to 12 months between IVUS- and Angiography guidance groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically-relevant bleeding</measure>
    <time_frame>11 months</time_frame>
    <description>The difference in clinically-relevant bleeding (BARC ≥2) will be calculated from 1 month to 12 months between SAPT and DAPT groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major adverse cardiovascular and cerebrovascular events (MACCE)</measure>
    <time_frame>11 months</time_frame>
    <description>The difference in MACCE will be calculated from 1 month to 12 months between SAPT and DAPT groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Net adverse clinical events (NACE)</measure>
    <time_frame>12 months</time_frame>
    <description>The difference in NACE between IVUS- and Angiography guidance groups, or SAPT and DAPT groups.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">3486</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>IVUS-guidance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the IVUS-guided DES implantation group, optimal stent deployment criteria included: 1) the MLA in the stented segment is &gt;5.0 mm^2, or 90% of the MLA at the distal reference segments; 2) plaque burden 5-mm proximal or distal to the stent edge is &lt;55%; and 3) absence of &gt;=Type B edge dissection. Further treatment will be required if any of those 3 criteria was not met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Angiography-guidance</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the Angiography-guided DES implantation group, stent diameter and length will be selected by visual estimation with a stent/artery ratio of 1.1:1.0. Post-dilation with a noncompliant balloon (balloon/stent diameter=1.0:1.0) inflated at &gt;18 atm will be performed for all lesions. Angiographic success is defined as Thrombolysis In Myocardial Infarction (TIMI) grade 3, residual stenosis &lt;20%, and the absence of &gt;Type B dissection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAPT group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor + aspirin for 1 month followed by ticagrelor plus matching placebo for an additional 11 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAPT group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ticagrelor + aspirin for 12 month.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AntiPlatelet therapy</intervention_name>
    <description>AntiPlatelet therapy with ticagrelor + aspirin or ticagrelor alone.</description>
    <arm_group_label>Angiography-guidance</arm_group_label>
    <arm_group_label>DAPT group</arm_group_label>
    <arm_group_label>IVUS-guidance</arm_group_label>
    <arm_group_label>SAPT group</arm_group_label>
    <other_name>ticagrelor, aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous coronary intervention</intervention_name>
    <description>PCI with DES implantation</description>
    <arm_group_label>Angiography-guidance</arm_group_label>
    <arm_group_label>DAPT group</arm_group_label>
    <arm_group_label>IVUS-guidance</arm_group_label>
    <arm_group_label>SAPT group</arm_group_label>
    <other_name>PCI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Enrollment into the study will require meeting at least one of these clinical syndromes&#xD;
        within 1 month.&#xD;
&#xD;
          -  Unstable angina, defined as rest pain for 5-30 minutes or deteriorative exertional&#xD;
             angina with either a) transient ST segment depression or elevation, or b) angiography&#xD;
             showing a visually estimated diameter stenosis ≥90% or a ruptured plaque or thrombotic&#xD;
             lesion&#xD;
&#xD;
          -  Non-ST elevation myocardial infarction (NSTEMI), defined as positive troponin&#xD;
             consistent with clinical syndrome.&#xD;
&#xD;
          -  ST elevation MI (STEMI)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable or unwilling to provide informed consent&#xD;
&#xD;
          -  Stroke within 3 months or any permanent neurologic deficit, and prior intracranial&#xD;
             bleed, or any intracranial disease such as aneurysm or fistula&#xD;
&#xD;
          -  Previous coronary artery bypass graft (CABG)&#xD;
&#xD;
          -  Any planned surgery within 90 days&#xD;
&#xD;
          -  Any reason why any antiplatelet therapy might need to be discontinued within 12 months&#xD;
&#xD;
          -  Severe chronic kidney disease defined as an estimated glomerular filtration rate&#xD;
             (eGFR) &lt; 20 ml/min/1.73m^2&#xD;
&#xD;
          -  Need for chronic oral anticoagulation (warfarin/coumadin or direct oral&#xD;
             anticoagulants)&#xD;
&#xD;
          -  Platelet count &lt; 100,000 mm^3&#xD;
&#xD;
          -  Contraindication to aspirin&#xD;
&#xD;
          -  Contraindication to ticagrelor&#xD;
&#xD;
          -  Liver cirrhosis&#xD;
&#xD;
          -  Women of child-bearing potential&#xD;
&#xD;
          -  Life expectancy &lt; 1 year&#xD;
&#xD;
          -  Any condition likely to interfere with study processes including medication compliance&#xD;
             or follow-up visits (e.g. dementia, alcohol abuse, severe frailty, long distance to&#xD;
             travel for follow-up visits, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shao-Liang Chen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Nanjing First Hospital, Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shao-Liang Chen, MD, PhD</last_name>
    <phone>+86-25-52208048</phone>
    <email>chmengx@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jing Kan, MPH</last_name>
    <phone>+86-25-52271398</phone>
    <email>kanjingok@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nanjing First Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaoliang Chen, MD</last_name>
      <phone>+86 13605157029</phone>
      <email>chmengx@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Jing Kan, MPH</last_name>
      <phone>+86 15305140515</phone>
      <email>kanjingok@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Zhang J, Gao X, Kan J, Ge Z, Han L, Lu S, Tian N, Lin S, Lu Q, Wu X, Li Q, Liu Z, Chen Y, Qian X, Wang J, Chai D, Chen C, Li X, Gogas BD, Pan T, Shan S, Ye F, Chen SL. Intravascular Ultrasound Versus Angiography-Guided Drug-Eluting Stent Implantation: The ULTIMATE Trial. J Am Coll Cardiol. 2018 Dec 18;72(24):3126-3137. doi: 10.1016/j.jacc.2018.09.013. Epub 2018 Sep 24.</citation>
    <PMID>30261237</PMID>
  </reference>
  <reference>
    <citation>Ge Z, Gao XF, Kan J, Kong XQ, Zuo GF, Ye F, Tian NL, Lin S, Liu ZZ, Shao YB, He YQ, Wen SY, Yang Q, Xia Y, Wang ZZ, Xiao PX, Li F, Zeng HS, Yang S, Wang Y, Tao L, Gao DS, Qu H, Qian XS, Han YL, Chen F, Zhang JJ, Chen SL. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial. Am Heart J. 2021 Jun;236:49-58. doi: 10.1016/j.ahj.2021.02.014. Epub 2021 Feb 20.</citation>
    <PMID>33621541</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 30, 2019</study_first_submitted>
  <study_first_submitted_qc>May 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing First Hospital, Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Shaoliang Chen, MD</investigator_full_name>
    <investigator_title>Vice President</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

